UBS Group’s Tobira Therapeutics, Inc. Common Stock TBRA Stock Holding History

UBS Group’s Portfolio TBRA Stock Details TBRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-80,022	Closed	-$3.18M	–	8401
2016 Q3	$3.18M	Buy	80,022 +79,489	+14,914%	+$887K	﹤0.01%	2436
2016 Q2	$7K	Buy	+533	New	+$4.96K	﹤0.01%	7015
2016 Q1	–	Sell	-2,504	Closed	-$25K	–	8638
2015 Q4	$25K	Buy	2,504 +1,125	+82%	+$11.7K	﹤0.01%	6538
2015 Q3	$13K	Buy	1,379 +1,212	+726%	+$17K	﹤0.01%	7109
2015 Q2	$3K	Buy	+167	New	+$2.44K	﹤0.01%	8134
2015 Q1	–	Sell	-4,797	Closed	-$39K	–	9856
2014 Q4	$39K	Buy	+4,797	New	+$41.3K	﹤0.01%	6816

UBS Group's TBRA Position: Q4 2016 in Review

UBS Group sold out of Tobira Therapeutics, Inc. Common Stock (TBRA) in Q4 2016, closing a stake of 80,022 shares — an estimated $3.18M sold.

UBS Group first reported a position in TBRA in Q4 2014 and held it in 6 quarters. The position peaked at $3.18M in Q3 2016. 0 funds tracked by Wall St. Rank hold TBRA as of Q4 2016.

UBS Group reported no remaining Tobira Therapeutics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
UBS Group sold 80,022 Tobira Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $3.18M.
UBS Group first reported a position in Tobira Therapeutics, Inc. Common Stock in Q4 2014 and held it in 6 quarters.
UBS Group's Tobira Therapeutics, Inc. Common Stock position peaked at $3.18M in Q3 2016.
0 funds tracked by Wall St. Rank held Tobira Therapeutics, Inc. Common Stock as of Q4 2016.

Based on UBS Group's 13F filing for Q4 2016, filed 14 Feb 2017.